These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

703 related items for PubMed ID: 34688290

  • 1. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF.
    Health Qual Life Outcomes; 2021 Oct 23; 19(1):247. PubMed ID: 34688290
    [Abstract] [Full Text] [Related]

  • 2. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, Ross Terres JA, Watts SD, Chen YF, Simpson EL, Silverberg JI.
    J Dermatolog Treat; 2022 May 23; 33(3):1521-1530. PubMed ID: 33222559
    [Abstract] [Full Text] [Related]

  • 3. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS® ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
    Silverberg JI, Lai JS, Patel KR, Singam V, Vakharia PP, Chopra R, Sacotte R, Kantor R, Hsu DY, Cella D.
    Br J Dermatol; 2020 Nov 23; 183(5):891-898. PubMed ID: 32107772
    [Abstract] [Full Text] [Related]

  • 4. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A.
    Br J Dermatol; 2019 Oct 23; 181(4):761-769. PubMed ID: 30729499
    [Abstract] [Full Text] [Related]

  • 5. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
    Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, Meunier J, ElMaraghy H, Sun L, Pierce E.
    Adv Ther; 2024 Apr 23; 41(4):1512-1525. PubMed ID: 38363461
    [Abstract] [Full Text] [Related]

  • 6. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
    Rosmarin D, Casillas M, Chen S, Dawson Z, Pierce E, Zhang H, Bukhalo M, Smith S.
    J Cutan Med Surg; 2022 Apr 23; 26(3):262-266. PubMed ID: 35086348
    [Abstract] [Full Text] [Related]

  • 7. Validity and reliability of a novel numeric rating scale to measure skin-pain in adults with atopic dermatitis.
    Silverberg JI.
    Arch Dermatol Res; 2021 Dec 23; 313(10):855-861. PubMed ID: 33547939
    [Abstract] [Full Text] [Related]

  • 8. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
    Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Peñas P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M.
    Dermatol Ther (Heidelb); 2021 Jun 23; 11(3):971-982. PubMed ID: 33899152
    [Abstract] [Full Text] [Related]

  • 9. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis.
    Puelles J, Fofana F, Rodriguez D, Silverberg JI, Wollenberg A, Dias Barbosa C, Vernon M, Chavda R, Gabriel S, Piketty C.
    Br J Dermatol; 2022 Feb 23; 186(2):285-294. PubMed ID: 34608623
    [Abstract] [Full Text] [Related]

  • 10. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
    Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, Sun L, Cardillo T, Nunes FP, Reich K.
    JAMA Dermatol; 2021 Jun 01; 157(6):691-699. PubMed ID: 33978711
    [Abstract] [Full Text] [Related]

  • 11. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
    Silverberg JI, Leshem YA, Calimlim BM, McDonald J, Litcher-Kelly L.
    Curr Med Res Opin; 2023 Oct 01; 39(10):1289-1296. PubMed ID: 37691437
    [Abstract] [Full Text] [Related]

  • 12. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
    Simpson EL, Bissonnette R, Paller AS, King B, Silverberg JI, Reich K, Thyssen JP, Doll H, Sun L, DeLozier AM, Nunes FP, Eichenfield LF.
    Br J Dermatol; 2022 Oct 01; 187(4):531-538. PubMed ID: 35442530
    [Abstract] [Full Text] [Related]

  • 13. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaçi D.
    Am J Clin Dermatol; 2024 May 01; 25(3):485-496. PubMed ID: 38528257
    [Abstract] [Full Text] [Related]

  • 14. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
    Rosmarin D, Fretzin S, Strowd L, Casillas M, DeLozier AM, Dawson Z, Chen S, Lu N, Thyssen JP.
    J Cutan Med Surg; 2022 May 01; 26(4):377-385. PubMed ID: 35354410
    [Abstract] [Full Text] [Related]

  • 15. Patient-reported outcome (PRO) instruments for disease severity and quality of life in patients with atopic dermatitis: a systematic review of English and Chinese literature.
    Li A, Zhang M, Yang Y, Zhang J, Xie X, Li X, Zhang H.
    Ann Transl Med; 2022 Aug 01; 10(16):906. PubMed ID: 36111032
    [Abstract] [Full Text] [Related]

  • 16. Validity and reliability of Patient-Reported Outcomes Measurement Information System Global Health scale in adults with atopic dermatitis.
    Schwartzman G, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, Chavda R, Gabriel S, Patel KR, Singam V, Kantor R, Hsu DY, Silverberg JI.
    J Am Acad Dermatol; 2021 Sep 01; 85(3):636-644. PubMed ID: 33484762
    [Abstract] [Full Text] [Related]

  • 17. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Ständer S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI.
    Dermatol Ther (Heidelb); 2024 May 01; 14(5):1127-1144. PubMed ID: 38696027
    [Abstract] [Full Text] [Related]

  • 18. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
    Thyssen JP, Buhl T, Fernández-Peñas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Ständer S.
    Dermatol Ther (Heidelb); 2021 Oct 01; 11(5):1599-1611. PubMed ID: 34275122
    [Abstract] [Full Text] [Related]

  • 19. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
    Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen YF, Sun L, Schloebe A, Riedl E, Cork MJ.
    Clin Exp Dermatol; 2023 Jul 21; 48(8):881-888. PubMed ID: 37032446
    [Abstract] [Full Text] [Related]

  • 20. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS® ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
    Br J Dermatol; 2020 Nov 21; 183(5):e149-e170. PubMed ID: 33135789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.